Fingolimod-associated PML in a patient with prior immunosuppression

Neurology

Volumn 86, Issue 19, 2016, Pages 1843-1845

  Gyang, Tirisham V ^a   Hamel, Johanna ^a   Goodman, Andrew D ^a   Gross, Robert A ^a   Samkoff, Lawrence ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CAPECITABINE; FINGOLIMOD; GLATIRAMER; GLUCOSE; INTERFERON BETA SERINE; NATALIZUMAB; OXALIPLATIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; COGNITIVE DEFECT; COLON CANCER; CONTRAST ENHANCEMENT; DYSARTHRIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; JC VIRUS; LYMPHOCYTE COUNT; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROLOGIST; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT DURATION;

FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84978405233     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002654     Document Type: Note

References (7)

1. Totaro R, Di Carmine C, Costantino G,. Fingolimod treatment in relapsing-remitting multiple sclerosis patients: a prospective observational multicenter postmarketing study. Mult Scler Int 2015; 2015: 763418.
2. Francis G, Kappos L, O'Connor P,. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 2014; 20: 471-480.
3. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm456919.htm. Accessed August 4, 2015.
4. Yousry TA, Pelletier D, Cadavid D,. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72: 779-787.
5. Bloomgren G, Richman S, Hotermans C,. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
6. Bartsch T, Rempe T, Wrede A,. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 2015; 78: 501-514.
7. Kappos L, Radue EW, O'Conner P,. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.